Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Normally, bone marrow produces all of the blood cells your child's body needs, but sometimes, genetic defects can disrupt the marrow's ability to make these vital cells. Dyskeratosis congenita (DC) is a rare genetic disorder that affects multiple parts
of the body, including the bone marrow's ability to make blood cells.
Children and young adults with dyskeratosis congenita are treated at Dana-Farber/Boston Children's through our Bone Marrow Failure and Myelodysplastic Syndrome Program,
recognized as one of the nation's best pediatric treatment and research programs for bone marrow failure and related conditions. Our patients have access to advanced treatments and diagnosis, including DNA mutation identification and ongoing clinical
trials investigating new treatments. Dana-Farber/Boston Children's is also home to one of the largest and most experienced pediatric stem cell transplant centers in the world. Stem cell (bone marrow) transplant is currently the only cure for the blood defects of DC.
Find more in-depth information on dyskeratosis congenita on the Boston Children's Hospital
website, including answers to:
New Patient Appointments